Celltrion’s Rituximab Biosimilar Is The First Greenlit By The FDA
Executive Summary
Truxima (rituximab-abbs) becomes the first biosimilar to Rituxan approved by the US agency, although launch timing remains unclear; Celltrion also has novel infliximab subcutaneous formulation accepted for review by the EMA.
You may also be interested in...
Amgen And Allergan File For US Rituximab
Amgen’s FDA submission for a biosimilar of Roche’s Rituxan rituximab brand comes shortly after Teva launched the first direct rival to the oncology drug in the US.
Teva Debuts US Rituximab At A 10% Discount
Teva and Celltrion have launched the first biosimilar rituximab in the US, introducing Truxima at a 10% discount to Roche’s Rituxan.
Pfizer Lines Up Trio Of US Biosimilar Launches
By mid-February next year, Pfizer plans to have introduced in the US bevacizumab, rituximab and trastuzumab biosimilars to Avastin, Rituxan and Herceptin.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Generics Bulletin?
Request a free trial today!
Register for our free email digests:
Register for our free email digests: